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Abstract
Background: In recent years the Illumina HumanMethylation450 (HM450) BeadChip has provided a user-friendly
platform to profile DNA methylation in human samples. However, HM450 lacked coverage of distal regulatory
elements. Illumina have now released the MethylationEPIC (EPIC) BeadChip, with new content specifically designed
to target these regions. We have used HM450 and whole-genome bisulphite sequencing (WGBS) to perform a
critical evaluation of the new EPIC array platform.
Results: EPIC covers over 850,000 CpG sites, including >90 % of the CpGs from the HM450 and an additional
413,743 CpGs. Even though the additional probes improve the coverage of regulatory elements, including 58 % of
FANTOM5 enhancers, only 7 % distal and 27 % proximal ENCODE regulatory elements are represented. Detailed
comparisons of regulatory elements from EPIC and WGBS show that a single EPIC probe is not always informative
for those distal regulatory elements showing variable methylation across the region. However, overall data from the
EPIC array at single loci are highly reproducible across technical and biological replicates and demonstrate high
correlation with HM450 and WGBS data. We show that the HM450 and EPIC arrays distinguish differentially
methylated probes, but the absolute agreement depends on the threshold set for each platform. Finally, we
provide an annotated list of probes whose signal could be affected by cross-hybridisation or underlying genetic
variation.
Conclusion: The EPIC array is a significant improvement over the HM450 array, with increased genome coverage of
regulatory regions and high reproducibility and reliability, providing a valuable tool for high-throughput human
methylome analyses from diverse clinical samples.
Keywords: EPIC, DNA methylation, HM450, Whole-genome bisulphite sequencing (WGBS), Microarray, Enhancers,
Validation
Background
DNA methylation is the most well-characterised epigen-
etic mark in humans. It is defined as the addition of a
methyl (CH3) group to DNA and in mammalian cells
occurs primarily at the cytosine of cytosine-guanine
dinucleotides (CpG). DNA methylation can modify the
function of regulatory elements and gene expression and
is therefore integral to normal human development and
biological functioning. Perturbations to normal DNA
methylation patterns can lead to dysregulation of cellular
processes and are linked with disease. Widespread aber-
rations in DNA methylation are a well-established hall-
mark of many cancers [1] and a growing body of
literature shows a role for DNA methylation in the aeti-
ology of other complex human diseases including




1Epigenetics Research Laboratory, Genomics and Epigenetics Division, Garvan
Institute of Medical Research, 384 Victoria St, Darlinghurst, Sydney 2010,
NSW, Australia
2St Vincent’s Clinical School, University of NSW, Sydney 2010, NSW, Australia
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pidsley et al. Genome Biology  (2016) 17:208 
DOI 10.1186/s13059-016-1066-1
A full understanding of the role of DNA methylation
in health and disease requires the development of tools
that can simultaneously measure DNA methylation
across large portions of the genome. The current ‘gold
standard’ technique for fine mapping of methylated cy-
tosines is whole-genome bisulphite sequencing (WGBS)
[5]. This is based on the treatment of genomic DNA
with sodium bisulphite, which converts unmethylated
cytosines to uracils while leaving methylated cytosines
unchanged, followed by whole-genome sequencing [6].
WGBS has been successfully applied to a range of bio-
logical tissues and cell lines to provide a complete map
of the ~28 million CpG sites in the human genome [7].
However, the high cost of this approach and significant
technical expertise currently required to generate and
process WGBS data means that it is not always the
most feasible method to interrogate DNA methylation
in large cohort studies.
In recent years, the Illumina Infinium BeadChips have
provided a popular, user-friendly alternative. Like WGBS,
this technology is based on sodium bisulphite conversion
of DNA, but with subsequent single base resolution geno-
typing of targeted CpG sites using probes on a microarray.
The advantage of the Infinium platforms is that they
are easy to use, time-efficient and cost-effective and
show good agreement with DNA methylation measure-
ments from other platforms [8]. For a full comparison
of the strengths and weaknesses of different DNA
methylation profiling methods, including Infinium
methylation arrays, MBDcap-Seq and reduced repre-
sentation bisulphite sequencing (RRBS), see the recent
review by Stirzaker and colleagues [5].
The Infinium methylation technology was first intro-
duced with the HumanMethylation27K BeadChip (HM27)
in 2008, which featured 25,578 probes predominantly
targeting CpG sites within the proximal promoter region
of 14,475 consensus coding sequence (CCDS) genes and
well-described cancer genes [8]. Probes were preferentially
designed to target CpG islands due to the established rela-
tionship between DNA methylation at promoter CpG
islands and gene expression [8]. The 12-sample per array
format and genome-wide span of HM27 represented a
significant advance over previous methods, which were
low-throughput and restricted to a small number of
genomic loci. HM27 allowed researchers to explore the
role of DNA methylation in carcinogenesis and identify
cancer biomarkers [9] and for the first time perform large-
scale ‘epigenome-wide association studies’ (EWAS), which
revealed the associations between DNA methylation
patterns and tobacco smoking [10], ageing [11] and other
complex human phenotypes.
In 2011, the HM450 BeadChip superseded the HM27
BeadChip. The HM450 retained the 12-sample per array
design and featured 485,577 probes, including probes
targeting 94 % of the CpG sites on the HM27 [12]. The
new content was selected after consultation with a
consortium of DNA methylation researchers and com-
prised a more diverse set of genomic categories, includ-
ing: CpG islands, shores and shelves, the 5′UTR, 3′UTR
and bodies of RefSeq genes, FANTOM4 promoters, the
MHC region and some enhancer regions [12]. The
improved coverage, together with the high sample
throughput, of the HM450 made it a popular tool for
EWAS studies and for the generation of reference
epigenomes, including the International Cancer Genome
Consortium (ICGC) and the International Human
Epigenome Consortium (IHEC). Notably, The Cancer
Genome Atlas (TCGA) consortium used the HM450
platform to profile more than 7500 samples from over
200 different cancer types [5] and it is the platform of
choice for large-scale epidemiological studies such as the
ARIES study, which is analysing 1000 mother-child pairs
at serial time points across their lifetime [13].
Although the HM450 has been widely embraced by
the epigenetics research community, the technology
initially presented some technical challenges. Foremost
among these was the two probe types on the HM450.
In order to assay the new genomic regions included on
the HM450, probes with a different chemistry were
added. However, the two probe types have a different
dynamic range, reflecting potential bias in the DNA
methylation measurements. Extensive discussion within
the field led to the development of bioinformatics
methods that now allow us to address the technical
impact of the two probe designs, as comprehensively
reviewed by Morris and Beck [14]. Additionally, both
the HM27 and HM450 featured a proportion of probes
that either hybridised to multiple regions of the genome
or targeted genetically polymorphic CpGs [15–17].
However, the thorough identification and annotation of
these probes means that we can now easily account for
misleading measurements during processing. Finally,
DNA methylation changes rarely occur in isolation and
are more likely to affect contiguous genomic regions. It
was therefore necessary to develop methods to accur-
ately identify these differentially methylated regions
(DMRs) from HM450 data. Today, a range of analytical
packages is available to researchers for regional methy-
lation analysis, for example [18–20]. In summary,
methods for processing and analysis of Infinium methy-
lation BeadChips have matured considerably over
recent years and we as a community are now extremely
proficient at handling this type of data.
The remaining concern with the HM450 platform was
that the probe design missed important regulatory regions.
Recent studies using other platforms such as WGBS have
demonstrated that DNA methylation at regulatory en-
hancers can determine transcription and phenotypic
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variation, through modulation of transcription factor
binding. Thus accurate quantification of DNA methylation
at more regulatory regions is essential for our understand-
ing of the role of DNA methylation in human develop-
ment and disease. To meet this need, Illumina have
recently released the Infinium MethylationEPIC (EPIC)
BeadChip, with new content specifically designed to target
enhancer regions [21]. The EPIC BeadChip contains over
850,000 probes, which cover more than 90 % of the sites
on the HM450, plus more than 350,000 CpGs at regions
identified as potential enhancers by FANTOM5 [22] and
the ENCODE project [23]. The EPIC array promises to be
an essential tool to further our understanding of DNA
methylation mechanisms in human development and
disease, in particular the DNA methylation landscape of
distal regulatory elements. In this paper we perform a
comprehensive evaluation of the new EPIC platform.
Results
General features of the Infinium platforms
The Infinium methylation platforms use bead technology
for highly multiplexed measurement of DNA methylation
at individual CpG loci on the human genome. Individual
beads hold oligos comprising a 23 base address, to allow
identification of their physical location on the BeadChip,
and a 50 base probe. Probe sequences are designed to be
complementary to specific 50 base regions of bisulphite
converted genomic DNA with a CpG site at the 3′ end of
the probe [8]. After hybridisation to bisulphite converted
DNA, single-base extension of the probe incorporates a
fluorescently labelled ddNTP at the 3′ CpG site to allow
‘genotyping’ of the C/T conversion that results from bisul-
phite conversion. The fluorescent signal is then measured.
The proportion of DNA methylation at a particular
CpG site (also called the methylation beta-value (β)) is
then ascertained by taking the ratio of the methylated
(C) to unmethylated (T) signal, using the formula: β =
intensity of the methylated signal/(intensity of the
unmethylated signal + intensity of the methylated sig-
nal + 100). A β-value of 0 represents a completely
unmethylated CpG site and a β-value approaching 1
represents a fully methylated CpG site.
There are two types of probe design on the Infinium
platforms. Type I probes have two separate probe
sequences per CpG site (one each for methylated and
unmethylated CpGs), whereas Type II probes have just
one probe sequence per CpG site (Fig. 1). This means
that, per CpG site assayed, Type II probes use half the
physical space on the BeadChip compared with Type I.
However, Type I probes are still necessary as their design
characteristics mean they can measure methylation at
more CpG dense regions than Type II probes. In this
study we consider the distribution of probe types on the
new EPIC array. However, their specific features and the
technical issues resulting from having two different
probe designs on the same platform have been discussed
for the HM450 array in depth elsewhere and are beyond
the scope of the current study [24–27].
Design, genomic distribution and functional classification
of probes on the EPIC array
To evaluate the new EPIC platform, we first compared the
design, genomic distribution and functional classification of
probes with those on the preceding HM450 BeadChip,
using the manufacturer supplied annotation data (Methyla-
tionEPIC_v-1-0_B2 and HumanMethylation450_1501748
2_v-1-2 manifest files). The EPIC platform has probes tar-
geting 866,836 cytosine positions on the human genome, of
which 863,904 (99.7 %) are CpG dinucelotides and 2932
(0.3 %) CNG targets. Additionally, there are 59 probes tar-
geting SNP sites to allow sample matching and 636 probes
for sample-dependent and sample-independent quality con-
trol. Comparison with the HM450 annotation data shows
that the EPIC includes 450,161 (93.3 %) of the HM450
CpG probes (Fig. 2a and b). Investigation of the 32,260
(6.7 %) HM450 CpG probes, excluded from the EPIC array
showed that the excluded probes were enriched for Type I
probes (odds ratio (OR) = 1.93, confidence interval (CI) =
1.89–1.98) and probes previously flagged as being unreli-
able (‘discard’) by Naeem et al. [17] (OR = 1.15, CI = 1.13–
1.18), suggesting that Illumina excluded some of the least
reliable probes on the HM450. We performed further ana-
lysis to identify the remaining HM450 and new EPIC
probes whose signal could be unreliable due to cross-
reactivity and underlying genetic variation. This revealed
43,254 cross-reactive probes with ≥ 47 bp homology with
an off-target site, of which 15,782 (36.5 %) are new to the
EPIC platform. We also identified overlap with genetic vari-
ant categories with minor allele frequency > 5 % at: (1) tar-
get CpG sites (n = 12,378); (2) single base extension sites of
Type I probes (n = 772); and (3) overlapping the probe body
(n = 97,345). For full-annotated lists, see Additional file 1:
Table S1; Additional file 2: Table S2; Additional file 3: Table
S3; Additional file 4: Table S4; Additional file 5: Table S5
and Additional file 6: Table S6.
The EPIC platform features 413,743 new CpG probes,
of which 95 % (n = 393,540) are Type II probes (Fig. 2a
and b). The high proportion of new Type II probes
reflects the increased coverage of distal regulatory ele-
ments, which are largely CpG-sparse regions of the
genome and so amenable to profiling by Type II probes.
Type II probes also take up less physical space on the
BeadChip, thus maximising probe number, however the
number of samples measured per BeadChip was reduced
from 12 on the HM450 to 8 on the EPIC.
To ascertain the genomic distribution of probes on the
EPIC array, we next calculated the number of probes
targeting promoters, gene body and intergenic regions
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Fig. 1 (See legend on next page.)
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using GENCODE V19 annotation data (Fig. 2c; Additional
file 7: Table S7). EPIC probes are principally located at
promoters (54 %), followed by gene bodies (30 %) and
then intergenic regions (16 %). We then took a closer look
at the distribution of new EPIC probes (new EPIC) as
compared to probes that are common between EPIC and
HM450 (EPIC/HM450). Interestingly, new EPIC probes
show increased targeting of gene bodies—32 % of new
EPIC probes (n = 133,021) versus 27 % of EPIC/HM450
probes (n = 122,158)—and intergenic regions—20 % of
new EPIC probes (n = 80,902) versus 13 % of EPIC/
HM450 probes (n = 58,507). Our next analysis revealed
that 19 % and 18 % of all EPIC probes are located in CpG
islands and CpG island shores, respectively. However, a
much smaller fraction of new EPIC probes is allocated to
these regions—6 % of new EPIC probes versus 31 % of
EPIC/HM450 probes at CpG islands and 12 % of new
EPIC probes versus 23 % EPIC/HM450 probes at CpG
island shores. Both new EPIC and EPIC/HM450 probes
are most commonly located in non-CpG island regions
(341,069 (82 %) and 206,589 (46 %), respectively).
The large number of new EPIC probes targeting gene
body, intergenic and non-CpG island regions is consist-
ent with Illumina’s intention to include new content
covering distal regulatory elements on the EPIC. To
explicitly test this, we took advantage of several publicly
available catalogs of regulatory elements, curated across
a wide range of cell types [28–30]. Thurman et al. [28]
used high-throughput profiling of DNase hypersensitive
sites (DHSs) to identify regions of open chromatin that
correspond to sites of transcription factor binding in
place of canonical nucleosomes; the most recent update
of this catalog [31] integrates DNase hypersensitivity
assays across 177 cell types and contains 3,166,489 regu-
latory regions which are further subdivided into prox-
imal (n = 607,894) and distal (n = 2,558,595) sites based
on distance to GENCODE V19 transcription start sites
[32]. We also included the FANTOM5 compendium of
43,011 transcribed enhancer regions identified through
computational mining of CAGE-Seq transcription data
from 432 primary cell, 135 tissue and 241 cell line
human samples [29].
Using these publicly available catalogs we identified
the EPIC probes targeting each type of regulatory region
and observed an increase in the number of new EPIC
probes targeting DNAse distal sites and FANTOM5
enhancers (Fig. 2c) (DNase distal new EPIC = 115,797
versus EPIC-HM450 = 82,168, FANTOM5 new EPIC =
21,070 versus EPIC-HM450 = 7763). Considering both
the new EPIC and EPIC-HM450 probes together, we
found that overall 27 % of DNAse proximal, 7 % of
DNAse distal and 58 % of FANTOM5 enhancers were
covered by probes on the EPIC array (Fig. 2d–f ). Thus
the proportion of all 607,894 DNAse proximal and
2,558,595 DNAse distal regions covered by the EPIC
array was low. However, DNAse elements vary by cell
type, so repeating the analysis for each cell type indi-
vidually we found that the proportion of covered regula-
tory elements per cell type was in the range of 39–57 %
(DNAse proximal) and 10–25 % of DNAse distal sites
(for individual cell type statistics, see Additional file 8:
Table S8). We then used the median number of occur-
rences of each DHS across the 177 cell types to subdiv-
ide the DHSs into those that are least frequently
occurring (specific) and most frequently occurring (com-
mon) (Additional file 7: Figure S1a, b). Interestingly, we
(See figure on previous page.)
Fig. 1 Infinium methylation probe design. a The difference in DNA methylation measurement process used by Illumina Infinium Type I and II
probes is demonstrated with two probes targeting adjacent CpG sites in the BRCA1 promoter. Both probes are present on EPIC and HM450
platforms. b Infinium I (cg21253966) and Infinium II (cg04110421) probes targeting two adjacent CpG sites in the BRCA1 promoter region; the
targeted CpG sites are highlighted in green. Each probe is designed to hybridise a 50 bp DNA sequence, underlined in blue, downstream of the
targeted CpG site. c DNA methylation measurement with Infinium I probes is carried out by two beads – the unmethylated (U) bead measures
the unmethylated signal and methylated (M) bead measures the methylated signal. The unmethylated signal detection for the cg21253966 probe
is schematically represented on the left panel. Briefly, the unmethylated bead probe (U) sequence is designed to match bisulphite converted DNA
sequence of the unmethylated locus. (Note that cytosines in both the target CpG site and all other CpG sites bound by the 50 bp probe are
assumed to be unmethylated and therefore converted to Ts during bisulphite reaction.) The hybridisation of a bisulphite converted unmethylated
DNA fragment to the bead enables single base extension and incorporation of a ddNTP labelled nucleotide matching the nucleotide
immediately upstream of the target CpG site; in this case incorporation of an A nucleotide and signal detection in the RED channel. Hybridisation
of the methylated bead probe (M), on the other hand, results in mismatch at the 3′ end of the probe and inhibition of single base extension.
Detection of the methylated signal, shown on the right panel, follows similar steps. d For Infinium II probes the unmethylated and methylated
signals are measured by the same bead (U/M). The bead probe sequence is designed to match bisulphite converted DNA of both the
methylated and unmethylated locus. This is achieved by making the cytosine of the target CpG site the single base extension locus and replacing
cytosines of all other CpG sites within the probe sequence with degenerate R bases that hybridises to both T (representing unmethylated and
converted cytosine) and C (representing methylated and protected cytosine) bases. The unmethylated signal detection for the cg04110421 probe
is schematically represented on the left panel. The hybridisation of the bisulphite converted unmethylated DNA fragment enables single base
extension and incorporation of ddNTP labelled A nucleotide matching the unmethylated and converted cytosine at the target CpG site and
signal detection on the RED channel. The detection of the methylation signal, shown on the right panel, is the same except that in this case
single base extension results in incorporation of ddNTP labelled G nucleotide matching the methylated and protected cytosine at the target CpG
site and signal detection on the GREEN channel
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observe that probes on the EPIC array cover 17 % and
4 % of the specific DHSs and 38 % and 11 % of the
common DHSs, for proximal and distal DHSs, respect-
ively (Additional file 7: Figure S1c, d and Additional file
8: Table S8).
Of the regulatory regions covered, most are repre-
sented by just one probe on the array (Fig. 2d–f ). For
example, of the 185,340 DNAse distal sites targeted by
probes on the EPIC array, 93 % (n = 172,406) are
targeted by only one probe (see Fig. 2e). It is currently
Fig. 2 Distribution of probes on the HM450 and EPIC platforms. a, b Venn diagrams indicating overlap of (a) Type I and (b) Type II CpG probes
on the HM450 and EPIC platforms. c Distribution of probes across different genome annotation categories: (1) GENCODE19 genes; (2) CpG
islands; and (3) regulatory regions defined using ENCODE DNAse hypersensitivity sites and FANTOM5 enhancers. Probes are separated according
to whether they are new to EPIC (‘EPIC new’, blue, n = 413,743) or common to HM450 and EPIC (‘EPIC/HM450’, purple, n = 450,161). d–f Fraction
of (d) DNase proximal peaks, (e) DNase distal peaks and (f) FANTOM 5 enhancers which overlap more than one, two or three HM450 probes
(red), EPIC probes (blue) or genomic CpG sites (grey)
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unknown if a single probe on the EPIC array can accur-
ately capture methylation variation across the extent of a
regulatory region, especially as regulatory regions are
less CpG dense than CpG islands and can show abrupt
methylation changes across the locus.
Reproducibility of the EPIC array
To assess the performance of the EPIC array we ran a
series of technical analyses using DNA from different
samples types (cell lines, clinical samples and blood)
commonly profiled in array-based methylation studies: a
transformed prostate cancer cell line (LNCaP); primary
cell cultures of prostate epithelial cells (PrEC); patient-
matched cancer associated fibroblasts (CAF) and non-
malignant tissue associated fibroblasts (NAF); and infant
blood from archival Guthrie cards. We first profiled the
DNA on both the HM450 and EPIC arrays. Initial qual-
ity control steps using the control SNP probes on the
array confirmed correct sample matching and demon-
strated the utility of these probes on the EPIC array
(Additional file 7: Figure S2).
DNA methylation β-value density plots showed that on
both platforms all samples had a bimodal distribution,
with the two peaks indicating unmethylated and fully
methylated states typical of DNA methylation data
(Fig. 3a). However, we noted that the unmethylated peak
was higher than the methylated peak in the HM450 data,
whereas the two peak heights were more similar in the
EPIC data. This likely reflects the new probe content on
the EPIC array, which (as described above) targets more
intergenic, non-CpG island regions, which are often meth-
ylated. To confirm this, we recreated the density plots
with only the probes common to both platforms (n =
450,161). As expected, this plot showed strong similarity
between the methylation density distribution of HM450
and EPIC for each matched sample (Fig. 3b). Finally, we
plotted the β-values from the EPIC array by Type I and
Type II probes separately and found that the distribution
of Type II probes was shifted relative to Type I, as
frequently reported in the HM450 literature (Fig. 3c).
To determine the reproducibility of DNA methylation
values of the same sample run on the EPIC array, we
hybridised technical replicates of the LNCaP and PrEC
cell lines on the same BeadChip. We found a high correl-
ation between β-values of the two sets of technical repli-
cates (Spearman rank correlation LNCaP ρ = 0.993; PrEC
ρ = 0.990) (Fig. 3d and e). Next, to assess the performance
of the EPIC array in comparison with other platforms we
extended our comparison of matched samples run on the
HM450 and EPIC array. Again Spearman rank correlation
tests showed an extremely high correlation of β-values
between the two platforms (LNCaP ρ = 0.976; PrEC ρ =
0.963; CAF C ρ = 0.981; NAF C ρ = 0.980; Guthrie card T-
73 ρ = 0.966) (Fig. 3d–f; Additional file 7: Figure S3).
These data indicate that the DNA methylation data gener-
ated from the EPIC array are extremely reproducible
across platforms and, importantly, is amenable for integra-
tion with existing HM450 data. Finally, we compared
EPIC DNA methylation values with matched whole
genome bisulphite sequencing data (average coverage >
X20), currently considered the gold-standard technique
for measuring DNA methylation. Again we found a high
correlation between platforms (LNCaP ρ = 0.935, PrEC
ρ = 0.917) (Fig. 3d and e). This is especially notable as
the WGBS and Infinium array DNA methylation
values are derived from different types of raw data
(continuous intensity values versus count-based reads,
respectively, which makes the array measurements of
DNA methylation less sensitive towards the extremes
of 0 and 1).
Reproducibility of differential analysis
Infinium methylation arrays are commonly used to identify
loci that are differentially methylated between sample
groups. To compare the ability of the HM450 and EPIC
array to distinguish differentially methylated probes
(DMPs), we used the limma package [33] to perform separ-
ate analyses on the two platforms and identified 4740 EPIC
and 2054 HM450 differentially methylated probes (DMPs)
between three matched pairs of CAFs and NAFs (unpaired
analysis; p < 0.001; Δβ > 0.1; see ‘Methods’). Approximately
half the EPIC DMPs are present as probes on the HM450
(2332/4740) (Fig. 4a). Of the 2332 common probes, ~57 %
(n = 1330) are also called as differentially methylated on
HM450 (see Fig. 4b). However, if we relax the p value cut-
off for HM450 DMP calling to p < 0.01, the number of
common probes that are DMPs on EPIC and HM450 is in-
creased to ~94 % (2184). We also observed excellent over-
all agreement in estimated Δβ-values of EPIC and HM450
data (Spearman rank correlation ρ = 0.98, p < 2.2E-16)
(Fig. 4c). An example of differential methylation called by
both EPIC and HM450 platforms is shown in a genomic
region spanning two CpG islands upstream of a gene pro-
moter (Fig. 4d). The region is densely covered by probes
and methylation data from both platforms reveal extensive
hypermethylation in CAF samples. Interestingly, more than
half of the EPIC DMPs are located in probes that are
unique to the EPIC array (n = 2408) (see Fig. 4a) and a
large fraction of these (n = 1026, 43 %) are located in distal
regulatory elements (see Fig. 4e). This highlights the ability
of the EPIC platform to interrogate and detect differential
methylation in previously inaccessible loci, especially those
located in regulatory regions.
Ability of EPIC to detect differential methylation at distal
regulatory elements
Several recent studies using whole-genome methylation
profiling methodologies demonstrated the important
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Fig. 3 (See legend on next page.)
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role of DNA methylation in modulating transcription
factor binding to regulatory elements of the genome at
regions distal to transcription start sites [34, 35]. There-
fore, the addition of regulatory regions on the EPIC
array is an important advance. However, as detailed
above, the majority of these regions are represented by
only one probe on the array (Fig. 2d–f ). To determine
the ability of a single probe to capture the methylation
status of an entire regulatory region, we compared EPIC
to WGBS methylation data in LNCaP and PrEC cells
across distal DHSs. Using an approach summarised in
Fig. 5a, we considered all reference distal DHSs as
defined across 177 cell lines by the ENCODE project
[31]. To ensure that we had enough DNA methylation
data for a meaningful analysis, we selected only the
reference distal DHSs containing three or more CpG
sites (n = 537,894). For each reference distal DHS, we
then computed the mean methylation level of (1) all
EPIC probes and (2) WGBS CpG loci to estimate the
methylation status over the DHS region; for the WGBS
data we only considered DHSs with 50X coverage. As
shown in Fig. 5b, PrEC WGBS and EPIC data were
informative for 464,790 (~86 %) and 92,954 (~17 %)
reference DHSs, respectively, while LNCaP WGBS and
EPIC data were informative for 495,591 (~92 %) and
92,912 (~17 %) reference DHSs, respectively (Additional
file 7: Figure S4a).
As a first step to check the quality of the data, we
tested whether DNA methylation at reference DHSs was
associated with closed chromatin. More specifically, we
used ENCODE DHS catalog annotation data to deter-
mine a subset of regions present in PrEC and LNCaP
cell lines. Using this cell-type specific DHS data, we
observed a strong negative relationship between the
methylation status of reference distal DHSs and the
presence of distal DHSs in both cell lines (Fig. 5c and d;
Additional file 7: Figure S4b and c). Specifically, WGBS
data show that the vast majority (~73 %; 27,087/37,200)
of the assayed PrEC distal DHSs are lowly methylated
(β ≤ 0.3) and only 3837 sites (~10 %) are extensively
methylated (β > 0.6); log-odds ratio of 3.63 (95 % CI
3.60–3.67) (Fig. 5c). Similarly, most LNCaP distal DHSs
assayed by WGBS are lowly methylated, 30,118 or ~67 %
and just 6801 sites (~15 %) are extensively methylated;
log-odds ratio of 2.49 (95 % CI 2.46–2.52) (Additional file
7: Figure S4b). The same relationship between methylation
and DHS status is observed with the EPIC methylation
data; PrEC log-odds ratio of 3.20 (95 % CI 3.14–3.26) and
LNCaP log-odds ratio of 2.61 (95 % CI 2.56–2.66) (Fig. 5d;
Additional file 7: Figure S4c).
Next, we performed a direct comparison of reference
distal DHS methylation values from WGBS and EPIC
PrEC data across DHSs common to both platforms
(PrEC: 85,908, LNCaP: 88,674). Methylation readouts
from the two platforms agree well with Spearman’s Rho
correlation coefficients of 0.883 for PrEC and 0.822 for
LNCaP (Fig. 6a and b). For PrEC and LNCaP, respect-
ively, 87 % and 80 % of regions showed < 20 % difference
between platforms; 61 % and 54 % showed < 10 % differ-
ence; and 33 % and 30 % showed < 5 % difference. For
example, the reference DHS re13.110396155 (located
~10 kb upstream of the prostate cancer associated IRS2
gene [36, 37]) presents as a DHS in PrEC but not in
LNCaP, and accordingly, WGBS data show the region to
be lowly methylated in PrEC and highly methylated in
LNCaP. Crucially, we found that a single EPIC probe in
the centre of the DHS accurately reflects the methyla-
tion status of the surrounding CpG sites (Fig. 6c).
Figure 6d highlights another example of an agreement
in DNA methylation readouts between the two plat-
forms at a reference DHS re22.41658115 present in
LNCaP but not PrEC cells. This DHS is located within
the gene body of RANGAP1, which has previously
been associated with signalling cascades in prostate
cancer [38].
Notably, only a small number of DHSs (PrEC: 432
or ~0.5 %; LNCaP: 1377 or ~ 1.5 %) show large dis-
agreements, i.e. lowly methylated (β ≤ 0.3) in WGBS
and heavily methylated (β > 0.6) in EPIC or vice versa
(Fig. 6a and b). Visual inspection of a subset of these
‘disagreement loci’, at reference DHSs present in a cell
line and heavily methylated according to EPIC, revealed
two common types of disagreement (Additional file 7:
Figures S5 and S6). The first occurs when the methylation
measurement of the EPIC probe is consistent with the
WGBS methylation measurement at the single CpG site
assayed, but due to probe positioning does not capture the
variable methylation across the DHS (Fig. 6e). The
second type of disagreement arises when the methyla-
tion measurement of the EPIC probe disagrees with the
WGBS methylation at the single CpG site assayed, as
well as the adjacent CpG sites, suggesting a technical
(See figure on previous page.)
Fig. 3 Comparison of methylation values on the HM450 and EPIC platforms. a, b Density plots of the methylation (beta) values for a subset of
samples profiled on both the HM450 and EPIC platforms, showing (a) all CpG probes on the HM450 (n = 482,421) and EPIC (n = 863,904) and (b)
only CpG probes that are common to HM450 and EPIC platforms (n = 450,161). c Density plot of methylation values for the same subset of
samples on the EPIC platform, showing shift in methylation values between Type I and II probes. d–f Scatter plots show correlation between
methylation measurements from different platforms: EPIC-EPIC, EPIC-HM450 and EPIC-WGBS for (d) LNCaP and (e) PrEC; and EPIC-HM450 for (f)
CAF, NAF and Guthrie samples
























































































































Fig. 4 Reproducibility of CAF vs. NAF differential analysis across HM450, EPIC and WGBS platforms. a Pie chart indicating number of differentially
methylated probes (DMPs) on the EPIC that are present on the HM450 array. b Segmented pie chart showing number of EPIC DMPs that are present
on the HM450 and the proportion that are also called as DMPs using HM450 data. c Scatter plot showing strong agreement in the direction and
magnitude of the estimated CAF-NAF methylation difference (Δ β-value) on the EPIC vs. HM450 at the EPIC DMPs. d Genomic region densely covered
by probes on the EPIC and HM450 arrays shows extensive differential methylation between CAF and NAF samples on both platforms. e Distribution of
DMPs across different genome annotation categories: (1) GENCODE19 genes; (2) CpG islands; and (3) regulatory regions defined using ENCODE DNAse
hypersensitivity sites and FANTOM5 enhancers. Probes are separated according to whether they are new to EPIC (blue, n = 2408) or common to
HM450 and EPIC (purple, n = 2332)
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artifact in the EPIC probe such as described for the
HM450 array [15–17] (Fig. 6f ).
Discussion
We have performed a comprehensive analysis of the new
EPIC methylation array and find it to be a robust and
reliable platform. The EPIC array almost doubles the
content of the preceding HM450 array, retaining the
majority of HM450 probes, and provides valuable new
content. Two types of probe chemistry are used on the
Infinium HM450 and EPIC methylation arrays. The new
probes on the EPIC are primarily Type II probes, which
take up less physical space on the array and are suitable
for targeting the less CpG dense regions of the genome.
The increase in Type II probe measurements is associ-
ated with a shifted distribution of methylation values
compared to the HM450. A number of methods to
correct for this are already available [24–27] and we
recommend that these should be utilised in data
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Fig. 5 Overview of approach and assessment of DNA methylation at distal regulatory elements defined using ENCODE DNAse hypersensitivity
data. a Outline of the approach taken to analyse the relationship between DNAse hypersensitivity and DNA methylation in LNCaP and PrEC cell
lines, using a schematic representation of the genome. b Venn diagram showing the sites that were informative in PrEC WGBS and EPIC
methylation data at ENCODE reference distal DHS sites. c, d Methylation status of DNAse sensitive and non-sensitive sites according to c) WGBS
and d) EPIC PrEC methylation data
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Fig. 6 (See legend on next page.)
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probes on the array may have a confounded signal due
to cross-reactivity or underlying genetic sequence vari-
ation. We have provided a full list of annotated probes
to aid identification and filtering for EPIC array users
in Additional file 1: Table S1; Additional file 2: Table
S2; Additional file 3: Table S3; Additional file 4: Table
S4; Additional file 5: Table S5 and Additional file 6:
Table S6.
Comparison of matched samples run on EPIC and
HM450 shows excellent agreement in methylation values
and in the ability to detect sites of differential methyla-
tion between samples. The convincing cross-platform
reproducibility paves the way for integration of new
EPIC data with existing HM450 datasets. The reliability
of the EPIC array for methylation evaluation is further
shown through comparison between matched samples
profiled on EPIC and WGBS. Even though the new
content on the EPIC array is designed to target distal
regulatory regions, the majority of regions are targeted
by just one probe. Remarkably, we found that at the
majority (~80 % of regions with a cross-platform differ-
ence < 20 %) of targeted distal regions the single EPIC
probe accurately represents DNA methylation across the
entire region. Where methylation at the EPIC probe did
not represent the distal regulatory region, the probes
were often located at CpG sites showing variable methy-
lation compared to adjacent CpGs. An array platform
will never be as comprehensive as WGBS, so researchers
planning a more detailed investigation of regulatory
regions would be advised to interrogate or validate
methylation patterns across a critical region of interest
using an independent technology.
Conclusion
The EPIC array represents a significant improvement in
genomic coverage compared to the HM450, in particular
with a higher proportion of probes capturing methyla-
tion at enhancers; however, the proportion of distal
regulatory elements interrogated is still limited and the
methylation level of one CpG probe per element is not
always reflective of the neighbouring sites. EPIC does, how-
ever, maintain many of the desirable features of the
HM450, such as ease of analysis and affordability, which al-
lows profiling of large sample numbers and integration with
valuable data resources generated from existing HM450
datasets, to allow for new important insights in genomic
regulation in disease states. As such, the new EPIC platform
will ensure methylation arrays remain a central tool in
epigenetic research while cost and complexity of bioinfor-
matic analysis still prohibits the large-scale use of WGBS.
Methods
DNA samples
LNCaP prostate cancer cells were cultured as described
previously [39]. Normal prostate epithelial cells were
cultured according to the manufacturer’s instructions in
prostate epithelial growth medium (PrEGM, catalogue no.
CC-3166; Cambrex Bio Science) as described previously
[40]. Genomic DNA for both cell lines was extracted using
QIAamp DNA Mini and Blood Mini kit following the
manufacturer’s protocol for cultured cells (Qiagen).
Three blood spot punches, each 3 mm in diameter,
were taken from 5–7-year-old archived neonatal screen-
ing (Guthrie) cards from five children whose mothers
participated in the DOMInO trial [41]. Written informed
consent was obtained from the mothers to access their
child’s newborn screening card for the purposes of iso-
lating DNA for (epi)genetic studies. DNA was extracted
using GenSolve technology (IntegenX) followed by puri-
fication using the QIAamp DNA micro kit (Qiagen) and
an additional ethanol precipitation step. The quantity of
the DNA samples was assessed using the Quant-iT
Picogreen dsDNA assay (Life Technologies).
Patient-matched cancer associated fibroblasts (CAFs)
and non-malignant tissue associated fibroblasts (NAFs)
(n = 3 pairs) were isolated and validated as previously
described [42]. DNA was extracted using the DNeasy kit
(Qiagen) with on-column RNase A digestion. DNA
quantity and quality was assessed using a NanoDrop
2000 and gel electrophoresis.
(See figure on previous page.)
Fig. 6 Ability of EPIC to detect differential methylation at distal regulatory elements defined using ENCODE DNAse hypersensitivity data. a, b
Scatter plot showing overall agreement in DNA methylation between EPIC probes and WGBS across distal regulatory regions for (a) PrEC and (b)
LNCaP. c–f. Comparison of DNA methylation between EPIC and WGBS across distal regulatory regions. Tracks show ENCODE DHS data across 177
reference cell lines and PrEC and LNCaP DHS data separately; EPIC and WGBS methylation measurements for PrEC and LNCaP; and WGBS
coverage for each site, with the 10X threshold represented by a dashed purple line for reference. Dark grey shading indicates regions that were
not assayed by each technology. c Genomic region shows agreement in DNA methylation between EPIC probe and WGBS across distal
regulatory region re13.110396155. PrEC features a DNAse sensitive peak and low methylation, while LNCaP lacks DNAse sensitivity and has high
methylation. d Genomic region shows agreement in DNA methylation between EPIC probe and WGBS across distal regulatory region
re22.41658115. LNCaP features a DNAse sensitive peak and low methylation, while PrEC lacks DNAse sensitivity and has high methylation. e
Genomic region shows disagreement in DNA methylation between EPIC probe and WGBS across distal regulatory region re2.153430015 due to
probe positioning. PrEC features a DNAse sensitive peak and high methylation at the border of the peak where the EPIC probe is located, but
low methylation in the centre of the peak (not covered by EPIC probes). f Genomic region shows disagreement in DNA methylation between
EPIC probe and WGBS, in both LNCaP and PrEC samples, across distal regulatory region re6.28654415
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Bisulphite conversion and Infinium arrays
DNA (250–750 ng) was treated with sodium bisulphite
using the EZ DNA methylation kit (Zymo Research, CA,
USA). For a full description of samples and replicates
run on the arrays see Additional file 7: Figure S2. DNA
methylation was quantified using the Illumina Infinium
HumanMethylation450 (HM450) and HumanMethyla-
tionEPIC (EPIC) BeadChip (Illumina, CA, USA) run on
an Illumina iScan System (Illumina, CA, USA) using the
manufacturer’s standard protocol.
Raw IDAT files were processed with Illumina’s Geno-
meStudio software V2011.1 and background normalised
using negative control probes to generate methylation β-
values which were used for all downstream analyses. We
used MethylationEPIC_v-1-0_B2 manifest for processing
EPIC data and HumanMethylation450_15017482_v-1-2
for HM450 data. All downstream analysis was conducted
using the hg19/GRCh37 human genome assembly.
Whole genome bisulphite sequencing
WGBS libraries were prepared for LNCaP/PrEC using
the Illumina Paired-end DNA Sample Prep Kit (Illumina,
CA, USA). Briefly, DNA (1 μg) was spiked with 0.5 %
unmethylated lambda DNA (Promega) in a final volume
of 50–65 μL. DNA was sheared to 150–300 bp by sonic-
ation with a Covaris S2. Library preparation was
performed according to the manufacturer’s protocol;
fragments were end-repaired and adenylated before
ligation of Illumina TruSeq adaptors. Gel size selection
(260–330 bp) was used to purify and size select the
ligated DNA, using Qiagen Gel extraction kit (Qiagen,
part #28704) and DNA was eluted in 20 μL H2O.
Bisulphite treatment was carried out as previously de-
scribed [43] with the bisuphite reaction performed for
4 h at 55 °C. After bisulphite cleanup, the DNA pellet
was resuspended in 50 μL H2O. The adaptor-ligated
bisulphite-treated DNA was enriched by performing five
independent polymerase chain reactions (PCRs) for ten
cycles using PfuTurboCx Hotstart DNA polymerase
(Stratagene) in a volume of 50 μL per PCR. The five in-
dependent PCRs were pooled together, cleaned up using
the MinElute PCR purification kit and eluted in 20 μL
Qiagen EB buffer. Library quality was assessed with the
Agilent 2100 Bioanalyzer using the High-sensitivity
DNA kit (Agilent, CA, USA). DNA was quantified using
the KAPA Library Quantification kit by quantitative
PCR (KAPA Biosystems). Paired-end 100 bp sequencing
was performed for each library on the Illumina HiSeq
2500 platform using Truseq v3 cluster kits and SBS kits.
Bisulphite reads were aligned to the human genome
using version 1.2 of an internally developed pipeline,
publicly available for download from http://github.com/
astatham/Bisulfite_tools. Briefly, adaptor sequences and
poor quality bases were removed using Trimgalore
(version 0.2.8, http://www.bioinformatics.babraham.a-
c.uk/projects/trim_galore/) in paired-end mode with
default parameters. Bismark v0.8.326 was then used to
align reads to hg19 using the parameters ‘-p 4 –bowtie2 –
X 1000 –unmapped –ambiguous –gzip –bam’. PCR dupli-
cates were removed using Picard v1.91 (http://broadinsti-
tute.github.io/picard). Count tables of the number of
methylated and unmethylated bases sequenced at each
CpG site in the genome were constructed using bismark_-
methylation_extractor with the parameters ‘-p –no_over-
lap –ignore_r2 4 –comprehensive –merge_non_CpG –
bedgraph –counts –report –gzip –buffer_size 20G’. The
PrEC and LNCaP libraries had a total of 908,201,217 and
1,271,535,305 reads, respectively. Both libraries passed
basic quality control checks with 88 %/87 % alignment
rate, ×20/×26 mean coverage and 99.7 %/99.7 % bisulphite
conversion for PrEC/LNCaP.
Public data
ENCODE DNAse hypersensitivity data were downloaded
from ENCODE data portal http://www.encodeproject.org/
data/annotations/v2 [31] in June 2015. We obtained a
master list of distal DNase peaks comprising 2,558,595
regions and list of proximal DNase peaks comprising
607,894 regions. We also obtained DNase signal data for
PrEC (ENCODE accession ENCFF001EEC) and LNCaP
(ENCODE accession ENCFF001DWI) cell lines.
FANTOM5 compendium of enhancer elements was
downloaded from FANTOM5 enhancer data portal http://
enhancer.binf.ku.dk/presets/[29] in November 2015. We
obtained a list of permissive enhancers comprising 43,011
regions.
CpG island coordinates were obtained from UCSC
browser. CpG island shores were obtained from CpG
island coordinates by taking 2 kb flanking regions and
subsequently removing any overlaps with CpG islands.
GENCODE v19 transcript annotations were down-
loaded from GENCODE data portal ftp://ftp.sanger.ac.uk/
pub/gencode/Gencode_human/release_19 [32]. Promoter
regions were defined as regions of +/–2 kb around tran-
scription start sites (TSSs). Gene body regions were
defined as transcripts plus 2 kb flanking upstream and
downstream regions, minus the promoter regions defined
above. Intergenic regions were defined as regions of the
genome not overlapping gene body or promoter regions.
Phase 3 variant data from the 1000 Genomes project




All analyses were conducted in the R statistical software
(Version > = 3.2.2).
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Coverage computations
For each annotation region we computed the number of
overlapping HM450 probes, EPIC probes and CpG loci.
The regions were then stratified based on the number of
overlaps: one or more overlaps (≥1), two or more over-
laps (≥2) and three or more overlaps (≥3).
Identification of probes overlapping genetic variants
The Bioconductor ‘VariantAnnotation’ package was used
to parse the 1000 Genomes VCF file and extract all
‘SNP’ and ‘INDEL’ variants overlapping EPIC probes. We
examined variant position with respect to EPIC probe
coordinates to further separate the variants into three
categories: (1) variants overlapping targeted CpG sites;
(2) variants overlapping single base extension sites for
Infinium Type I probes; and (3) variants overlapping the
rest of the EPIC probe, 48 base pairs for Infinium Type I
probes and 49 base pairs for Infinium Type II probes.
Results were filtered to only include genetic variants
with a maximum minor allele frequency >0.05.
Identification of cross-reactive probes
We followed the written description in [16] to identify
regions of potential cross-reactivity using the BLAT
alignment tool [45]. For EPIC probes that were common
to the HM450, we were able to reproduce Chen et al.’s
results with 99.998 % precision and 99.883 % recall
(True positive: 1,281,444; False positive: 23; False nega-
tive: 1497—BLAT matches from probe sequences com-
mon to both platforms). We then extended this protocol
to include all new probes on EPIC. Probe sequences with
equal homology to more than one in silico genome are
reported as ties. BLAT results are reported as zero-based
coordinates.
Comparison to WGBS data
To compare EPIC DNA methylation readouts at single
CpG loci to WGBS, we only considered EPIC targeted
CpG sites with × 10 or more coverage in WGBS data.
Given the high average coverage of our PrEC (LNCaP)
WGBS data, more than 95 % (96 %) of EPIC probes were
included in the comparison.
Differential methylation
We used the limma Bioconductor package [33] to
perform differential methylation analysis between CAF
and NAF samples on HM450 and EPIC datasets. We
only considered probes for which there is a reliable
methylation readout (detection p value < 0.01) in all six
samples. We then transformed β-values into M-values
using logit transformation: M ¼ log2 β1−β
 
. (To avoid
extreme M-values the β-values were capped at 0.01 and
0.99.) Standard limma workflow with unpaired contrast
was then applied to computed M-values to call HM450
and EPIC differentially methylated probes.
Methylation status of distal DHS elements
For this analysis, we only considered distal DHS ele-
ments overlapping 3 or more CpGs (n = 537,894). For
WGBS data, we computed average methylation levels for
distal DHS regions with X50 or more coverage to reduce
readout variability due to insufficient coverage. The aver-
age methylation level of a region was computed as the
ratio of the number of unconverted CpGs (C readouts)
to the total number of CpGs (C and T readouts) from
all the WGBS reads overlapping the region. For EPIC
data, we computed average methylation levels for distal
DHS regions by averaging β-values for all probes over-
lapping the region; we used a single technical replicate
from each sample. Only probes with robust signal inten-
sities (detection p value < 0.01) were used. Thus for our
analysis we had valid methylation values for 495,591 (or
92 %) regions from LNCaP WGBS data, for 464,790 (or
85 %) regions from PrEC WGBS data, for 92,912 (or
17 %) regions from LNCaP EPIC data and 92,954 (or
17 %) regions from PrEC EPIC data. We used ENCODE
DHS annotation data to identify subset of DHSs with 3
or more CpGs present in PrEC and LNCaP cell lines.
There are 40,469 sites present in PrEC with 37,200 sites
interrogated by WGBS and 13,166 sites by EPIC. There
are 47,616 sites present in LNCaP with 44,930 sites
interrogated by WGBS and 13,921 sites by EPIC.
Additional files
Additional file 1: Table S1. Cross-reactive probes on the EPIC array.
Tabulated counts per probe of potentially cross-reactive regions
(with ≥ 47 base pair homology). (CSV 97 kb)
Additional file 2: Table S2. Genomic regions complementary to
cross-reactive probes on the EPIC array with ≥ 48 base pair
homology. Individual BLAT hits corresponding to the cross-reactive
regions in Additional file 1: Table S1. Zero-based coordinates are
used. Hits homologous with the reverse complement have been oriented in
the forward direction, to be consistent with the annotation in the Illumina
manifest file. Reads map to either forward methylated (FM), forward
unmethylated (FU), reverse methylated (RM), reverse unmethylated (RU),
forward methylated and unmethylated (FMU), or reverse methylated and
unmethylated (RMU) in silico versions of the genome. (CSV 28778 kb)
Additional file 3: Table S3. Genomic regions complementary to
cross-reactive probes on the EPIC array with 47 base pair homology.
Individual BLAT hits corresponding to the cross-reactive regions in
Additional file 1: Table S1. Zero-based coordinates are used. Hits
homologous with the reverse complement have been oriented in the
forward direction, to be consistent with the annotation in the
Illumina manifest file. Reads map to either forward methylated (FM),
forward unmethylated (FU), reverse methylated (RM), reverse
unmethylated (RU), forward methylated and unmethylated (FMU), or
reverse methylated and unmethylated (RMU) in silico versions of the
genome. (CSV 46885 kb)
Additional file 4: Table S4. Probes overlapping genetic variants at
targeted CpG sites. (CSV 1336 kb)
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Additional file 5: Table S5. Probes overlapping genetic variants at
single base extension sites for Infinium Type I probes. (CSV 45 kb)
Additional file 6: Table S6. Probes with genetic variants overlapping
the body of the probe: 48 base pairs for Infinium Type I probes and 49
base pairs for Infinium Type II probes. (CSV 11599 kb)
Additional file 7: Table S7. Supplemental Table and Figures.
(PDF 1627 kb)
Additional file 8: Table S8. Distribution of EPIC probes across the
regulatory regions of individual cell types defined using ENCODE DNAse
hypersensitivity data. (XLS 46 kb)
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